In the case of pancreatic cancer, treatment with the PI3K inhibitors LY294002 and wortmannin led to a significant decrease in the expression of GLUT1 and subsequently, a reduction in the glucose uptake by cells (Melstrom et al., 2008). The gene discussed is PIK3CD; the disease is familial pancreatic carcinoma.